Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 10/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180083 | 0.98 | TSHR (0.53) | LTA4HTDP1TSHRPOLB | |
| SCHEMBL8623642 | 0.92 | ALDH1A1 (0.55) | CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL3583393 | 0.90 | HRH3 (0.54) | CYP2D6CYP2C19 | |
| SCHEMBL2182155 | 0.87 | LTA4H (0.51) | LTA4HTDP1POLB | |
| SCHEMBL826085 | 0.86 | NPC1 (0.54) | LTA4HPOLB | |
| SCHEMBL3960266 | 0.83 | ALDH1A1 (0.37) | LTA4HTDP1TSHRPOLBCYP2D6 | |
| SCHEMBL5656583 | 0.81 | ESR1 (0.37) | LTA4HTSHRCYP2D6 | |
| SCHEMBL2183678 | 0.80 | NOS3 (0.47) | — | |
| SCHEMBL6292255 | 0.80 | HRH3 (0.54) | LTA4HPOLBCYP2D6CYP2C19 | |
| SCHEMBL2180630 | 0.79 | LTA4H (0.55) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107879975-B | Histone deacetylase inhibitor and application thereof | 中国科学院上海药物研究所 | 2022-07-26 | — | — | CN | claimed |
| EP-1845973-B1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LTD (GB) | 2015-08-12 | — | — | EP | claimed |
| JP-4681548-B2 | — | — | 2011-05-11 | — | — | JP | claimed |
| US-7745638-B2 | Anticancer agents; such as 4-acetylamino-1H-pyrazole-3-carboxylic acid (4-fluoro-phenyl)-amide | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-29 | — | — | US | claimed |
| EP-2049106-A2 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-04-22 | — | — | EP | claimed |
| EP-2046330-A2 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-04-15 | — | — | EP | claimed |
| EP-2046327-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2009-04-15 | — | — | EP | claimed |
| EP-2043635-A2 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-04-08 | — | — | EP | claimed |
| US-20090036435-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2009-02-05 | — | — | US | claimed |
| US-20080269207-A1 | Anticancer agents; such as 4-acetylamino-1H-pyrazole-3-carboxylic acid (4-fluoro-phenyl)-amide | ASTEX THERAPEUTICS, LTD. (GB) | 2008-10-30 | — | — | US | claimed |
| JP-2006528163-A | — | — | 2006-12-14 | — | — | JP | claimed |
| US-20060194843-A1 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections; 4-(2,6-difluoro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methyl-piperidin-4-yl)-amide | ASTEX THERAPEUTICS LIMITED (GB) | 2006-08-31 | — | — | US | claimed |
| WO-2006077424-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | claimed |
| WO-2006077428-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | claimed |
| WO-2006077425-A1 | COMBINATIONS OF PYRAZOLE KINASE INHIBITORS AND FURTHER ANTITUMOR AGENTS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-27 | — | — | WO | claimed |
| EP-1651612-A1 | 3,4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | Astex Therapeutics Limited (GB) | 2006-05-03 | — | — | EP | claimed |
| WO-2005012256-A1 | 3, 4-DISUBSTITUTED 1H-PYRAZOLE COMPOUNDS AND THEIR USE AS CYCLIN DEPENDENT KINASES (CDK) AND GLYCOGEN SYNTHASE KINASE-3 (GSK-3) MODULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-02-10 | — | — | WO | claimed |
| EP-1482931-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | Transtech Pharma, Inc. (US) | 2004-12-08 | — | — | EP | claimed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | claimed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036435-A1 | Pharmaceutical Compounds | CDK9, CDK4, CDK19 | LTA4H 2711/4885TDP1 3652/4885TSHR 72/4885 |
| US-20060194843-A1 | 4-(2,6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide; anticancer agents; carcinoma of the colon; antifungal agents; antitumor agents; infections; 4-(2,6-difluoro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methyl-piperidin-4-yl)-amide | CDK1, CDK3, ROS1 | LTA4H 3058/4885TDP1 3618/4885TSHR 1205/4885 |
| US-20080269207-A1 | Anticancer agents; such as 4-acetylamino-1H-pyrazole-3-carboxylic acid (4-fluoro-phenyl)-amide | CDK1, CDK4, CDK3 | LTA4H 2808/4885TDP1 2863/4885TSHR 954/4885 |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | LTA4H 2743/4885TDP1 2323/4885TSHR 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.